In this week’s View, Dr. Eagle explores a study on the effect of low-dose aspirin vs. placebo on the development of anemia. He then discusses the PARAGLIDE-HF study on the use of ARNI agents in patients with mildly reduced or preserved ejection fraction and worsening heart failure. Finally, Dr. Eagle looks at the very important study on the value of bempedoic acid in primary prevention for patients who are statin-intolerant.

Twitter Links:

• Dr. Kim Eagle: @keaglemd
• American College of Cardiology: @ACCinTouch

Clinical Topics: Anticoagulation Management, Cardiac Surgery, Diabetes and Cardiometabolic Disease, Dyslipidemia, Geriatric Cardiology, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Cardiac Surgery and Arrhythmias, Cardiac Surgery and Heart Failure, Lipid Metabolism, Nonstatins, Novel Agents, Statins, Acute Heart Failure, Heart Failure and Cardiac Biomarkers, Acute Coronary Syndromes

Keywords: Aged, Anemia, Anemia, Iron-Deficiency, Anticoagulants, Aspirin, Ferritins, Frail Elderly, Geriatrics, Hemoglobins, Hemorrhage, Primary Prevention, Quality of Life, Angiotensins, Blood Pressure, Diuretics, Heart Failure, Hyperkalemia, Hypotension, Natriuretic Peptide, Brain, Neprilysin, Patient Readmission, Renal Insufficiency, Stroke Volume, Valsartan, Vasodilator Agents, Atherosclerosis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cholesterol, LDL, Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Risk Factors, Secondary Prevention, Stroke, Vascular Diseases, EaglesEyeView

< Back to Listings